Transaction DateRecipientSharesTypePriceValue
20th October 2020Jay T Flatley3,000Open or private sale$320.95$962,850.00
20th October 2020Jay T Flatley1,000Open or private sale$324.01$324,010.00
12th October 2020Susan H Tousi200Open or private sale$350.00$70,000.00
7th October 2020Jay T Flatley1,000Open or private sale$324.01$324,010.00
7th October 2020Susan H Tousi100Open or private sale$325.00$32,500.00
6th October 2020Jay T Flatley3,000Open or private sale$317.79$953,370.00
5th October 2020Kathryne Gambrell Reeves1,187Grant/award etc.$0.00
5th October 2020Joydeep Goswami115Payment by withholding$316.17$36,359.55
1st October 2020Francis A De Souza559Open or private sale$307.78$172,049.02
1st October 2020Francis A De Souza785Open or private sale$306.99$240,987.15
Illumina logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of -7/10.

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.

Ticker: ILMN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1110803
Employees: 7700
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Inventory, Net: $435 M (0%)
Assets, Current: $4 B (-5%)
Property, Plant and Equipment, Net: $890 M (0%)
Other Assets, Noncurrent: $552 M (42%)
Assets: $7 B (0%)
Long-term Debt, Current Maturities: $503 M (0%)
Accounts Payable, Current: $135 M (-9%)
Accrued Liabilities, Current: $477 M (0%)
Liabilities, Current: $1 B (67%)
Long-term Debt, Excluding Current Maturities: $659 M (0%)
Other Liabilities, Noncurrent: $230 M (13%)
Common Stock, Value, Issued: $2 M (0%)
Retained Earnings (Accumulated Deficit): $4 B (5%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $14 M (180%)
Treasury Stock, Value: $34 Th (12%)
Liabilities and Equity: $7 B (0%)
Revenue: $633 M (0%)
Gross Margin: $428 M (-59%)
Research and Development: $155 M (-50%)
Operating Income/Loss: $96 M (0%)
Other Income, net: $69 M (21%)
Provision for income taxes: $118 M (-3%)
EPS (basic): $0.32 (-78%)
EPS (diluted): $0.32 (-78%)